Table 4.

Statistically Significant Treatment Discontinuations – Antimuscarinic versus Placebo

Outcome	Total Comparisons	Total Studies	All Studies	Oxybutynin IR	Oxybutynin ER	Tolterodine IR	Tolterodine ER	Trospium	Darifenacin	Solifenacin	Fesoterodine
			RR (95% CI)	RR (95% CI)(Szonyi et al., 1995)	RR (95% CI)(Lackner et al., 2008)	RR (95% CI)(Malone-Lee et al., 2001)	RR (95% CI)(DuBeau et al., 2012; Wagg et al., 2014; Zinner et al., 2002)	RR (95% CI)(Sand et al., 2011)	RR (95% CI)(Chapple et al., 2007a; Foote et al., 2005)	RR (95% CI)(Wagg et al., 2006)	RR (95% CI)(DuBeau et al., 2012; Kraus et al., 2010b; Wagg et al., 2013)
AEs	13	12	1.41 (1.12–1.78) NNH = 47.4	--	2.78 (0.12–4.57)	3.53 (0.47–26.56)	1.02 (0.67–1.56)	1.14 (0.28–4.57)	0.78 (0.42–1.48)[45,42]	1.44 (0.89–2.33)	1.96 (1.45–2.64)[50,47,51] NNH =22.5
Dry Mouth	6	5	3.01 (1.18–7.68) NNH =86.3	--	--	0.64 (0.06–6.91)	2.61 (0.31–22.25)	--	2.51 (0.12–51.90)[45]	--	4.79 (1.16–19.74)[50,47,51] NNH =60.8

^*I² >25%;

^†Adverse Event noted in Study but 0 count

AEs = Adverse Events; CI = confidence intervals; ER = extended release; IR = immediate release; NNH = Number Needed to Harm; RR = rate ratio